Akèy › Kansè Poumon ki pa ti selil › New York › Rochester
Etid klinik pou Kansè Poumon ki pa ti selil nan Rochester, NY
13 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Ap rekriteFaz 3
- Wilmot Cancer Institute ( Site 0141), Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Rochester
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- University of Rochester Medical Center, Rochester
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Rochester General Hospital Infectious Disease, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 3
- University of Rochester, Rochester
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Ap rekriteVolontè an sante akeyi
- University of Rochester, Rochester
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- University of Rochester Medical Center, Rochester
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Ap rekriteFaz 1
- University of Rochester, Rochester
- University of Rochester, Rochester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster · 10 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Rochester, Rochester
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Ap rekriteFaz 2
- University of Rochester, Rochester
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Rochester
- Leksemi mieloïd egi16 etid
- Kansè poumon15 etid
- Kansè nan tete15 etid
- Kansè (tout kalite)14 etid
- Obèsite14 etid
- Sipwa13 etid
- Kansè pwostat10 etid
- Kansè Metastatik8 etid
- Myelom Miltip8 etid
- Kansè vejik7 etid
- Distrofi myotonik7 etid
- Kansè pankreyas7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.